Macquarie downgrades Charter Hall Retail REIT (MQV) to a Sell
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Currently, the analyst consensus on Charter Hall Retail REIT is a Moderate Buy with an average price target of €2.27.
Based on Charter Hall Retail REIT's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of €158.6 million and a net profit of €108.6 million. In comparison, last year the company earned a revenue of €109.4 million and had a GAAP net loss of €42.1 million
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Prologis (PLD) Receives a Buy from UBS
UBS analyst Michael Goldsmith reiterated a Buy rating on Prologis today and set a price target of $120.00. The company's shares opened today at $108.38. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Goldsmith covers the Real Estate sector, focusing on stocks such as Prologis, Agree Realty, and Boston Properties. According to TipRanks, Goldsmith has an average return of -0.1% and a 46.46% success rate on recommended stocks. In addition to UBS, Prologis also received a Buy from Wells Fargo's Blaine Heck in a report issued yesterday. However, on July 7, Mizuho Securities maintained a Hold rating on Prologis (NYSE: PLD). PLD market cap is currently $103.8B and has a P/E ratio of 27.55.
Business Insider
an hour ago
- Business Insider
Compass Therapeutics (CMPX) Gets a Buy from Stifel Nicolaus
Stifel Nicolaus analyst Stephen Willey reiterated a Buy rating on Compass Therapeutics today and set a price target of $11.00. The company's shares opened today at $2.66. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Willey covers the Healthcare sector, focusing on stocks such as Incyte, Bicara Therapeutics Inc., and Exelixis. According to TipRanks, Willey has an average return of 2.0% and a 40.34% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Compass Therapeutics with a $13.20 average price target, which is a 396.24% upside from current levels. In a report released on July 1, Raymond James also initiated coverage with a Buy rating on the stock with a $9.00 price target. CMPX market cap is currently $373.4M and has a P/E ratio of -6.74. Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CMPX in relation to earlier this year. Most recently, in May 2025, Thomas Schuetz, the CEO of CMPX bought 10,000.00 shares for a total of $21,100.00.
Business Insider
an hour ago
- Business Insider
UBS Sticks to Their Buy Rating for EQT (EQT)
In a report released today, Josh Silverstein from UBS reiterated a Buy rating on EQT, with a price target of $64.00. The company's shares opened today at $55.45. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Silverstein covers the Energy sector, focusing on stocks such as EOG Resources, Hess, and Baker Hughes Company. According to TipRanks, Silverstein has an average return of 7.1% and a 59.88% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for EQT with a $62.88 average price target, implying a 13.40% upside from current levels. In a report released on July 11, Roth MKM also assigned a Buy rating to the stock with a $69.00 price target. Based on EQT's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $2.42 billion and a net profit of $242.14 million. In comparison, last year the company earned a revenue of $1.31 billion and had a net profit of $103.49 million Based on the recent corporate insider activity of 73 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EQT in relation to earlier this year. Most recently, in April 2025, Jeremy Knop, the CFO of EQT sold 7,216.00 shares for a total of $368,016.00.
